CAS NO: | 1383716-33-3 |
包装 | 价格(元) |
10mM (in 1mL DMSO) | 电议 |
5mg | 电议 |
10mg | 电议 |
50mg | 电议 |
100mg | 电议 |
Cas No. | 1383716-33-3 |
化学名 | 1-((2-((2-chloropyridin-4-yl)amino)-4'-(cyclopropylmethyl)-[4,5'-bipyrimidin]-2'-yl)amino)-2-methylpropan-2-ol |
Canonical SMILES | CC(CNC1=NC=C(C(CC2CC2)=N1)C3=NC(NC4=CC(Cl)=NC=C4)=NC=C3)(O)C |
分子式 | C21H24ClN7O |
分子量 | 425.91 |
溶解度 | DMSO: 38 mg/mL |
储存条件 | Store at -20℃ |
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
产品描述 | IC50: 25 nM VPS34-IN1 is a Vps34 inhibitor. The vacuolar protein sorting 34 (Vps34) class III phosphoinositide 3-kinase (PI3K) phosphorylates phosphatidylinositol (PtdIns) to generate PtdIns(3)P that regulates membrane trafficking processes through its ability to recruit a subset of proteins possessing PtdIns(3)P-binding phox homology (PX) and FYVE domains. In vitro: VPS34-IN1 was identified to be able to inhibit in-vitro Vps34, but did not significantly inhibit the activity of tested 340 protein kinases or 25 lipid kinases that include all isoforms of class I and class II PI3Ks. Treatment of VPS34-IN1 to cells dose-dependently induced a quick dispersal of a specific PtdIns(3)P-binding probe, without altering the ability of class I PI3K to regulate Akt. Moreover, VPS34-IN1 could also induce a quick ~50-60% loss of SGK3 phosphorylation within 1 min. However, VPS34-IN1 could not inhibit activity of the SGK2 isoform without a PtdIns(3)P-binding PX domain. In addition, the combination of VPS34-IN1 and class I PI3K inhibitor of GDC-0941 resulted in the reduced SGK3 activity ~80-90%. Therefore, these data demonstrated that VPS34-IN1 would be a useful probe to delineate physiological roles of the Vps34 and the combination of class I such as GDC-0941 and class III such as VPS34-IN1 PI3K inhibitors could be used to better analyse the roles and regulation of the elusive class II PI3K [1]. In vivo: So far, there is no animal in vivo data reported. Clinical trial: Up to now, VPS34-IN1 is still in the preclinical development stage. Reference: |